Tonix reports preliminary TONMYA revenue of $14.0M to $15.0M for Q3 2026

Tonix Pharmaceuticals Holding Corp. filed an 8-K on October 15, 2026, sharing preliminary, unaudited figures for the quarter ended September 30, 2026, ahead of its full financial close.

For the three months ended September 30, 2026, the company's net revenue for TONMYA is estimated to be between $14.0 million and $15.0 million.¹ As of September 30, 2026, the company estimates its cash and cash equivalents were approximately $162.8 million.¹

Tonix cautioned that these numbers are not final. The estimated results are preliminary and were prepared by management based on its own estimates and currently available information, and remain subject to revision from quarter-end closing procedures, completion of consolidated financial statements, and other operational steps.¹ The company stated it has not completed its financial closing procedures for the quarter and that actual results could differ materially from this preliminary information, which should not be viewed as a representation of actual results.¹

Tonix noted that during preparation of its financial statements it may identify items requiring material adjustments to the preliminary figures, and advised prospective investors to exercise caution and avoid drawing inferences from the disclosure.¹ The company also said the preliminary information should not substitute for full financial statements prepared under U.S. GAAP and reviewed by its auditors.¹

The filing did not include additional details on pipeline programs, clinical trial timelines, or regulatory steps for this reporting period. The report was signed by Chief Financial Officer Bradley Saenger on October 15, 2026.